Compare Heron Therapeutics Inc (HRTX) vs Prospect Capital Corporation (PSEC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Heron Therapeutics Inc vs Prospect Capital Corporation — how do they compare? Heron Therapeutics Inc trades at $0.47 (market cap $91.46M), while Prospect Capital Corporation trades at $2.23 (market cap $1.12B). The key difference: Prospect Capital Corporation is far larger — about 12.2× Heron Therapeutics Inc's market cap, and Prospect Capital Corporation pays a 22.42% dividend while Heron Therapeutics Inc pays none. Which is the better fit depends on your goals.
| HRTX | PSEC | |
|---|---|---|
Market Cap | $91.46M | $1.12B |
Sector | Health | Financials |
52-Week High | $1.96 | $3.47 |
52-Week Low | $0.39 | $2.15 |
Enterprise Value | $189.36M | — |
Dividend Yield | — | 22.42% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HRTX trades at $0.4804, up 2.06% today, with a bullish technical signal despite mixed earnings. The stock shows a low price-to-sales ratio of 0.51 but negative profitability, with a net income margin of -20.53% in 2026. Recent Q1 2026 earnings missed expectations, though management reaffirmed full-year guidance. Analyst consensus is strongly bullish with 94.7% buy ratings.
Outlook remains speculative given persistent losses and cash burn, but potential upside exists if operational improvements materialize. Key risks include patent litigation outcomes and reliance on revenue growth to achieve profitability. Investors should weigh high analyst optimism against fundamental challenges.
PSEC trades at $2.235, down 0.67% on the day, with a bearish technical signal and neutral oscillators. The stock shows a deeply discounted P/B ratio of 0.38 but alarming fundamentals, including a negative revenue of -$407M and a net income margin of -495.94% for 2025. Recent quarterly EPS has consistently beaten estimates, and the company maintains regular dividend payments. Analyst consensus is mixed, with 25% buy ratings but a majority hold recommendation.
The outlook for PSEC is highly speculative. The extreme discount to book value and high dividend yield present a potential value opportunity, but this is overshadowed by severe profitability issues and negative cash flow. Investment carries significant risk due to the company's inconsistent revenue history and bearish market sentiment, requiring careful consideration of the underlying asset quality.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →About Prospect Capital Corporation
Prospect Capital Corp is a closed-end investment company based in the United States. Its investment objective is to generate both current income and long-term capital appreciation through debt and equity investments. The company invests primarily in senior and subordinated debt and equity of private companies for acquisitions, divestitures, growth, development, recapitalizations, and other purposes. It makes investments, including lending in private equity, sponsored transactions, directly to companies, investments in structured credit, real estate, and syndicated debt.
Read more on PSEC →
